Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hetrombopag plus Dexamethasone in Newly Diagnosed ITP
NCT05943691Phase 2Unknown
- Sponsor
- Shandong University
- Start
- Sep 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of hetrombopag in primary immune thrombocytopenia (ITP) (2 arms), sponsored by Shandong University. Primary endpoint: 26 week sustained overall response to ITP treatments. Status: unknown.
02
Drugs
hetrombopag
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT05943691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05943691.